Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from AbbVie, Inc; Adaptive Biotechnologies; and Amgen, Inc.

Taking Action With Minimal Residual Disease: Technique, Role, and Utilization of MRD to Improve Outcomes in Patients With Hematologic Malignancies

Release Date: January 07, 2021
Expiration Date: January 07, 2022

Activity Overview

This online, on-demand archived webcast brings together renowned experts in the role of measurable (or minimal) residual disease (MRD) in optimal management of hematologic malignancies including acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). In this educational program, these experts will leverage a combination of brief didactic presentations followed by engaging panel discussion to help place advances in MRD assessment into the context of patient care. In addition to examining available and emerging strategies for MRD monitoring throughout the care continuum, the expert panel also will discuss updates in treatment strategies for hematologic malignancies.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc; Adaptive Biotechnologies; and Amgen, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

These activities are intended for medical oncologists, hematologists, and other oncology health care professionals interested in the latest advances in MRD monitoring for patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in MRD monitoring for patients with hematologic malignancies are also invited to attend.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify the advantages and challenges associated with available techniques for the monitoring of MRD.
  • Assess the role of MRD monitoring in the management of hematologic malignancies based on best evidence and consensus guidelines.
  • Apply emerging data regarding the role of MRD assessment to clinical scenarios for patients with hematologic malignancies.
  • Evaluate the current and future role of MRD status as an efficacy measurement in clinical trials.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Nitin Jain, MD
Nitin Jain, MD
Associate Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Pharmacyclics, AbbVie, Genentech, AstraZeneca, Bristol Myers Squibb, Pfizer, ADC Therapeutics, Incyte, Servier Laboratories, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Aprea Therapeutics, Fate Therapeutics; Other: Advisory Board/Honoraria: Pharmacyclics, Janssen Pharmaceutica, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier Laboratories, Precision Biosciences, BeiGene, TG Therapeutics, ADC Therapeutics.

Lori Muffly, MD, MS
Lori Muffly, MD, MS
Assistant Professor of Medicine
Stanford University
Stanford, CA

Disclosures: Grant Research Support: Adaptive Biotechnologies, Astellas Pharma, Jasper Therapeutics; Consultant: Amgen, Pfizer, CareDx.

Mark Roschewski, MD
Mark Roschewski, MD
Lymphoid Malignancies Branch, Center for Cancer Research
National Cancer Institute, National Institutes of Health
Bethesda, MD

Disclosures: No relevant financial relationships with commercial interests to disclose.

Nina Shah, MD
Nina Shah, MD
Associate Professor of Medicine
University of California San Francisco
San Francisco, CA

Disclosures: Grant Research Support: Celgene/Bristol Myers Squibb, Janssen Pharmaceutica, Bluebird Bio, Sutro Biopharma, TeneoBio, Poseida Therapeutics, Nektar Therapeutics; Consultant: GlaxoSmithKline, Amgen, Indapta Therapeutics, Sanofi, Bristol Myers Squibb, CareDx, Kite Pharma, Karyopharm.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By